Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme – P4HA1 prolyl hydroxylase ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme – P4HA1 prolyl hydroxylase, is strongly induced in ...

Stock analysts at HC Wainwright issued their FY2029 earnings estimates for Akebia Therapeutics in a research note issued on ...

Vafseo ® (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to treat anemia due ...

Turkish drugmaker Er-Kim has signed a distribution agreement with Germany’s MEDICE Health Family to commercialize Vafseo ...

The global anemia treatment market was valued at USD 10.0 billion in 2022 and is expected to grow to USD 14.9 billion by 2028 ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Salk scientists discover protein first identified at Salk in 1996 called PIN1 encourages tumor growth in bladder cancer, then ...

Akebia has since engaged with the FDA on potentially expanding vadadustat treatment to this patient population and has received feedback on a protocol submitted for a Phase 3 cardiovascular outcome ...

Geode Capital Management LLC raised its holdings in shares of FibroGen, Inc. (NASDAQ:FGEN – Free Report) by 3.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC ...

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...